Clinical trialNCT00874614UnknownPhase 2Interventional

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

SponsorMolecular Insight Pharmaceuticals, Inc.Enrollment74ParagangliomaPheochromocytoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This clinical trial is designed to evaluate the effectiveness and collect additional safety information on AZEDRA® (iobenguane I 131) for the treatment of metastatic or relapsed/refractory (to other treatment) or unresectable pheochromocytoma or paraganglioma. The purpose of this trial is to test the use of AZEDRA® as a treatment for pheochromocytoma and paraganglioma, a rare disease. This Phase II study will help determine primarily if using the drug reduces the amount of blood pressure medication being taken as a result of the cancer and secondarily to determine such things as the effectiveness of the study drug in treating the cancer, additional safety measures, and to assess if the drug helps the quality of life and use of pain medication. All subjects will receive an imaging dose with scans followed by two therapeutic doses given approximately 3 months apart.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bennett Chin, MD
Duke University
Principal Investigator
clinicaltrials.gov ↗
Camillo Jimenez, MD
MD Anderson Cancer
Principal Investigator
clinicaltrials.gov ↗
Daniel Pryma, MD
University of Pennsylvania
Principal Investigator
clinicaltrials.gov ↗
Jeffrey Olsen, MD
Mallinckrodt Institute of Radiology Washington University
Principal Investigator
clinicaltrials.gov ↗
Joseph Dillon, MD
University of Iowa
Principal Investigator
clinicaltrials.gov ↗
Lale Kostakoglu, MD
Icahn School of Medicine at Mount Sinai
Principal Investigator
clinicaltrials.gov ↗
Lilja Solnes, MD
Johns Hopkins University
Principal Investigator
clinicaltrials.gov ↗
Michael H Pampaloni, MD
University of California at San Francisco
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California-San Francisco
San Francisco, California, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
University of Iowa
Iowa City, Iowa, United States
Johns Hopkins University
Baltimore, Maryland, United States
Washington University School of Medicine, Alvin J. Siteman Cancer Center
St Louis, Missouri, United States
Mount Sinai School of Medicine
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 Jun 2009
Primary completion: 14 Feb 2017
Completion: 28 Feb 2021
Last update posted: 20 Feb 2020
Registered enrollment: 74
Registry id: NCT00874614

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.